Sonoma Pharmaceuticals Inc
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2023 · Filed Feb 8, 2024
SNOA$1.13+1.8%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(In thousands, except share amounts)
| December 31, 2023 | March 31, 2023 | |
|---|---|---|
| (Unaudited) | ||
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $2,406 | $3,820 |
| Accounts receivable, net | 2,876 | 2,572 |
| Inventories, net | 2,955 | 2,858 |
| Prepaid expenses and other current assets | 4,009 | 4,308 |
| Current portion of deferred consideration, net of discount | 256 | 240 |
| Total current assets | 12,502 | 13,798 |
| Property and equipment, net | 397 | 488 |
| Operating lease, right of use assets | 341 | 418 |
| Deferred tax asset | 922 | 949 |
| Deferred consideration, net of discount, less current portion | 378 | 505 |
| Other assets | 78 | 73 |
| Total assets | $14,618 | $16,231 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $864 | $841 |
| Accrued expenses and other current liabilities | 1,847 | 2,029 |
| Deferred revenue | 75 | 100 |
| Deferred revenue Invekra | 63 | 60 |
| Short-term debt | 44 | 431 |
| Operating lease liabilities | 181 | 256 |
| Total current liabilities | 3,074 | 3,717 |
| Long-term deferred revenue Invekra | 101 | 140 |
| Withholding tax payable | 4,591 | 4,235 |
| Operating lease liabilities, less current portion | 160 | 162 |
| Total liabilities | 7,926 | 8,254 |
| Commitments and Contingencies (Note 5) | – | – |
| Stockholders’ Equity | ||
| Convertible preferred stock, $0.0001 par value; 714,286 shares authorized at December 31, 2023 and March 31, 2023, respectively, no shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively | – | – |
| Common stock, $0.0001 par value; 24,000,000 shares authorized at December 31, 2023 and March 31, 2023, respectively, 13,684,333 and 4,933,550 shares issued and outstanding at December 31, 2023 and March 31, 2023, respectively (Note 7) | 2 | 5 |
| Additional paid-in capital | 202,795 | 200,904 |
| Accumulated deficit | (193,282) | (189,514) |
| Accumulated other comprehensive loss | (2,823) | (3,418) |
| Total stockholders’ equity | 6,692 | 7,977 |
| Total liabilities and stockholders’ equity | $14,618 | $16,231 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.